Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

Innovent Biologics and Takeda (TAK) closed a global strategic collaboration effective Dec 4, 2025 to jointly develop and commercialize next‑generation IO and ADC therapies.

Rhea-AI Summary

Innovent Biologics and Takeda (TAK) closed a global strategic collaboration effective Dec 4, 2025 to jointly develop and commercialize next‑generation IO and ADC therapies.

Key deal terms: $1.2B upfront including a $100M equity investment at HK$112.56/share, plus up to $10.2B in development and sales milestones (total deal value up to $11.4B), and potential royalties outside Greater China. Takeda obtains exclusive rights to IBI343 outside Greater China, co‑development/co‑commercialization and U.S. co‑commercial rights for IBI363, and an option for IBI3001 (Phase 1).

Positive

• $1.2B upfront payment to Innovent
• Equity investment of $100M at HK$112.56 per share
• Deal carries up to $10.2B in milestone payments
• Takeda granted exclusive IBI343 rights outside Greater China
• Co‑development and U.S. co‑commercialization of IBI363

Negative

• Major future value ($10.2B) contingent on achieving milestones
• Innovent limited to royalties outside Greater China for most assets
• Innovent receives 40% of U.S. profits for IBI363 (40/60 split)

Argus Dec 5 session

-0.70% close to close Open Argus

Details

News Market Reaction – TAK

On Dec 5, the first trading day after this news, TAK closed 0.70% below the previous close.

Data tracked by StockTitan Argus for the Dec 5 session.

Key Figures

Upfront payment: US$1.2 billion Equity investment: US$100 million Share price for equity: HK$112.56 per share +3 more

Upfront payment

US$1.2 billion

Takeda upfront to Innovent under the partnership

Equity investment

US$100 million

Takeda equity investment in Innovent at HK$112.56 per share

Share price for equity

HK$112.56 per share

Price for new Innovent shares issued to Takeda

Milestone potential

US$10.2 billion

Development and sales milestones for IBI363, IBI343, IBI3001

Total deal value

US$11.4 billion

Maximum aggregate value including upfront and milestones

U.S. profit split

40/60 Innovent/Takeda

Profit or loss sharing for IBI363 in the U.S.

Historical Context

5 past events · Latest: Nov 07

5 events

1. Nov 07

   Clinical data update

   24h Move

   +0.1%

   Interim Phase 1b mezagitamab data showed sustained kidney benefits and safety.

2. Nov 03

   Clinical trial results

   24h Move

   -0.1%

   Seven-year Phase 3 dengue vaccine data showed durable efficacy and safety.

3. Oct 30

   Earnings and outlook

   24h Move

   -3.9%

   H1 FY2025 results with profit declines and impairment-driven outlook update.

4. Oct 27

   Product launch update

   24h Move

   +1.1%

   Availability of HyHub devices in U.S. to simplify HYQVIA infusion preparation.

5. Oct 21

   Oncology partnership

   24h Move

   +0.2%

   Initial announcement of global oncology collaboration with Innovent on IBI363/IBI343.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, antibody-drug conjugate, adc, bispecific, +2 more

6 terms

immuno-oncology medical

"next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

antibody-drug conjugate medical

"next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

adc medical

"including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC)"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

bispecific medical

"IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

phase 1 medical

"IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

equity investment financial

"including a US$100 million equity investment in Innovent through new share issuance"

An equity investment is buying ownership in a company by purchasing its shares, which gives you a claim on future profits and a portion of the company's value. It matters to investors because returns depend on the company’s growth and performance—like owning a slice of a pie that can grow or shrink—so you can gain through rising share prices or dividends but also risk losing value if the business falters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2^α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, "IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent's deep understanding of these assets, combined with Takeda's extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward."

Under the agreement:

• Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
• Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.
• Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China.

Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).

Detailed information about the collaboration can be found at the official website of Innovent Biologics.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

 

View original content:https://www.prnewswire.com/news-releases/innovent-biologics-announces-closing-of-global-strategic-partnership-with-takeda-for-next-generation-io-and-adc-therapies-302633652.html

SOURCE Innovent Biologics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Innovent and Takeda announce on Dec 4, 2025 about IBI363 and IBI343?

They closed a global collaboration to co‑develop IBI363 and granted Takeda exclusive rights to develop and commercialize IBI343 outside Greater China.

How much did Takeda pay Innovent upfront in the Dec 4, 2025 deal?

Takeda paid an upfront of $1.2 billion, including a $100 million equity investment.

What is the total potential value of the Innovent‑Takeda partnership (TAK)?

The agreement carries up to $10.2 billion in milestones, for a total potential deal value of $11.4 billion.

What commercial rights did Takeda receive for IBI343 in the Takeda (TAK) deal?

Takeda received exclusive global rights to develop, manufacture, and commercialize IBI343 outside Greater China.

What equity terms were included in the Takeda (TAK) investment in Innovent on Dec 4, 2025?

Takeda invested $100 million through new share issuance at a price of HK$112.56 per share.

What financial split applies to IBI363 sales in the U.S. under the Takeda (TAK) agreement?

U.S. profits or losses for IBI363 will be shared 40% Innovent / 60% Takeda.